Recent advances in the frontline treatment of metastatic renal cell carcinoma
作者机构：Department of Biomedical Sciences and Human OncologyUniversity of Bari‘A.Moro’Bari 70124Italy Division of Medical OncologyA.O.U.Consorziale Policlinico di BariBari 70124Italy Division of Translational OncologyI.R.C.C.S.Istituti Clinici Scientifici MaugeriPavia 27100Italy
出 版 物：《Journal of Cancer Metastasis and Treatment》 (癌症转移与治疗（英文版）)
年 卷 期：2021年第7卷第1期
页 面：695-706页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Renal cell carcinoma immune checkpoint inhibitors antiangiogenics survival
摘 要：We aim to describe the most recent advances in the upfront treatment of metastatic renal cell carcinoma,and to provide criteria-though often subjective-which could be used for treatment selection,by means of a critical review of the results of novel trials of immune-based combinations,coupled with personal considerations and *** date,5 immune-based combinations have been tested within large phase III trials;four of them yielded a significant overall survival benefit(Ipilimumab+Nivolumab,Pembrolizumab+Axitinib,Nivolumab+Cabozantinib and Pembrolizumab+Lenvatinib),while the combination of Avelumab+Axitinib,although reaching study primary endpoint,determined just a significant progression-free survival *** terms of safety,the excess of adverse events is overall counterbalanced to the higher activity of the ***,all the discussed immune-based combinations were ultimately approved by different regulatory authorities,and are indeed included in the most important international *** for longer follow-ups and more mature trial data,as well as for real-world experiences,in the absence of validated biomarkers,our 1st line treatment choice cannot but rely on methodologically incorrect treatment comparisons,personal preferences,and experience.
维普期刊数据库